Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) Net Margin (2017 - 2025)

VYNE Therapeutics' Net Margin history spans 9 years, with the latest figure at 8.0% for Q2 2025.

  • For Q2 2025, Net Margin fell 250.0% year-over-year to 8.0%; the TTM value through Dec 2025 reached 6.27%, down 89.0%, while the annual FY2025 figure was 44.39%, 4979.0% up from the prior year.
  • Net Margin reached 8.0% in Q2 2025 per VYNE's latest filing, down from 4.0% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 7507.87% in Q1 2022 to a low of 7531.03% in Q4 2022.
  • Average Net Margin over 5 years is 867.15%, with a median of 47.37% recorded in 2023.
  • Peak YoY movement for Net Margin: soared 1171395bps in 2022, then plummeted -751787bps in 2023.
  • A 5-year view of Net Margin shows it stood at 1171.43% in 2021, then crashed by -543bps to 7531.03% in 2022, then skyrocketed by 99bps to 47.37% in 2023, then skyrocketed by 80bps to 9.64% in 2024, then increased by 17bps to 8.0% in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Net Margin are 8.0% (Q2 2025), 4.0% (Q1 2025), and 9.64% (Q4 2024).